Human growth hormone is a blunt instrument in metabolic research. It mobilises lipid, but it also drives IGF-1 output, cellular proliferation and changes in glucose handling, so any effect measured in an adipocyte model is hard to attribute to lipolysis alone. This article sets out how AOD-9604 isolates the fat-oxidation domain of hGH, how it compares with unmodified Fragment 176-191 and with beta-lipotropin fragments, and what those differences mean for assay design, readouts and reagent handling in the lab.
Why the lipolytic domain is worth isolating
hGH is a 191-residue polypeptide whose biological activity is not evenly distributed along the chain. The fat-reducing behaviour of the molecule is concentrated in the C-terminal region, whereas the anabolic and growth-signalling behaviour depends on the intact protein engaging the full-length growth hormone receptor. In the whole hormone those two properties travel together, which is exactly the problem for anyone trying to run a controlled fat-oxidation experiment.
The practical consequences of using whole hGH as a lipolytic stimulus are well known:
- Direct triglyceride breakdown cannot easily be separated from downstream IGF-1 signalling.
- The insulin resistance and hyperinsulinaemia associated with whole growth hormone shift the metabolic baseline you are measuring against.
- Proliferative effects change the cell population itself over a multi-day incubation, which quietly changes your denominator.
Isolating the C-terminal fragment removes those confounders. What remains is a stimulus that acts on the adipocyte and very little else.
What AOD-9604 actually is
AOD-9604 is a synthetic analogue of the lipolytic C-terminal domain of human growth hormone, spanning residues 177 to 191, carrying an engineered tyrosine residue at the N-terminus. It is best understood as the fat-oxidation domain of hGH with a stability modification built in, rather than as a growth hormone analogue in any meaningful sense.
Two characteristics define its usefulness as a reagent:
- Selective lipolysis. It stimulates the breakdown of triglycerides and inhibits lipogenesis directly within adipocytes, without measurable effects on protein synthesis.
- Metabolic cleanliness. Because it lacks binding affinity for the full-length hGH receptor, it does not trigger IGF-1 production or alter glucose homeostasis, and it does not reproduce the hyperinsulinaemia and insulin resistance seen with whole growth hormone.
That combination is what makes it an elegant tool for analytical work. You get the lipolytic arm of growth hormone biology in isolation, with a far shorter list of variables to control for.
AOD-9604 versus hGH Fragment 176-191
The two sequences target the same lipolytic domain, but they behave differently once they are sitting in culture media at 37 degrees.
Standard Fragment 176-191 is prone to rapid enzymatic cleavage and to unfolding of its secondary structure in vitro. Over a long incubation this produces a decaying stimulus: the concentration you nominally applied is not the concentration acting on the cells at the end of the run, and replicate-to-replicate variance climbs accordingly.
The added tyrosine in AOD-9604 changes that. The modification substantially improves molecular stability and resistance to cellular peptidases, and it does so while retaining the fragment's lipolytic activity, so the pharmacology of the domain is preserved while the durability improves. In practice this shows up as two things:
- Enhanced half-life. The peptide holds its active monomeric conformation for longer in incubation media than the unmodified fragment does.
- Consistent lipolysis. Glycerol and free fatty acid release in white adipose tissue models is markedly more reproducible across wells and across runs.
Beta-lipotropin fragments as a comparator
Beta-lipotropin and its specialised fragments are classic endocrinology tools that have returned to favour in fat-oxidation work. Transcribed from the POMC precursor, these sequences bind directly to melanocortin receptors on the adipocyte surface and initiate triglyceride breakdown without requiring any secondary hepatic processing. That makes them a dependable positive control and a good way to establish baseline lipolysis rates in a cellular assay before introducing a test compound.
Choosing between the three
| Property | AOD-9604 | hGH Fragment 176-191 | Beta-lipotropin fragments |
|---|---|---|---|
| Origin | hGH C-terminus, residues 177-191 | hGH C-terminus, residues 176-191 | POMC precursor, beta-lipotropin |
| Key structural feature | Engineered N-terminal tyrosine | Unmodified native sequence | Native lipotropin sequence |
| Adipocyte engagement | Lipolytic signalling retained (mechanism under study) | Lipolytic fragment activity | Direct melanocortin receptor binding |
| Full-length hGH receptor | No meaningful affinity | No meaningful affinity | Not applicable |
| Stability in culture media | High, peptidase resistant | Lower, rapid enzymatic cleavage | Sequence dependent |
| Best suited to | Long incubations, kinetic and dose-response work | Short-window comparative studies | Baseline and positive-control lipolysis |
The lipolytic cascade and what you can measure
The readouts available to you follow directly from the mechanism. Receptor engagement on the adipocyte surface stimulates adenylate cyclase, producing a sharp rise in intracellular cAMP. That cascade phosphorylates hormone-sensitive lipase, which hydrolyses stored triglyceride and releases free fatty acids and glycerol into the culture medium.
Each step gives you something to quantify:
- cAMP accumulation as an early, proximal signal of receptor engagement.
- Hormone-sensitive lipase phosphorylation by immunoblot, confirming the cascade rather than inferring it.
- Glycerol release into the medium, the standard stoichiometric proxy for triglyceride hydrolysis.
- Free fatty acid release, useful alongside glycerol because re-esterification can decouple the two.
Because AOD-9604 does not perturb glucose homeostasis or protein synthesis, these readouts can be interpreted without first correcting for a shifted metabolic baseline. That is the whole point of using the isolated domain.
Purity, stability and handling
Modified peptide fragments are fragile, and the kinetic differences described above are subtle enough that reagent quality determines whether you can see them at all. A partially degraded lot will still produce lipolysis; it will simply produce it at an unknown effective concentration, which is worse than no signal because it looks like data.
Three points matter in practice:
- Synthesis precision. Truncated or deletion sequences in a lot shift the true molar concentration of active peptide. Every Pepsup lot is verified by independent European HPLC testing.
- Thermal history. Sourcing through Chinese dropshipping typically means weeks of uncontrolled heat exposure in ocean freight. Our in-stock items are held in temperature-controlled European facilities and shipped domestically, so the material arrives with its enzymatic activity intact.
- Laboratory storage. Keep lyophilised material cold and dark, reconstitute immediately before use, aliquot to avoid repeated freeze-thaw cycles, and treat reconstituted stock as short-lived.
Where it fits in a metabolic research panel
AOD-9604 is most valuable when you need the lipolytic arm of growth hormone biology cleanly separated from everything else the hormone does. Run it alongside a lipotropin fragment as a mechanistic control, or against unmodified Fragment 176-191 when the question is stability rather than potency. It also serves as a useful reference stimulus when characterising other compounds in our metabolic research range, since its effects are narrow enough to make a comparison interpretable.
Full sequence details, batch documentation and current European stock for AOD-9604 and related lipolytic fragments are listed in the Pepsup shop.
All products supplied by Pepsup are for laboratory research use only. Not for human or veterinary consumption, and not for diagnostic or therapeutic use.